License Holder Agreement Signing with Lantu Biopharma (Guangzhou) Co., Ltd

Strengthening Our Mission in Advanced Gene Therapy

We are proud to announce that Icare Biotech Co., Ltd. has officially signed a License Holder Agreement with Lantu Biopharma (Guangzhou) Co., Ltd. on 1st July 2025 in Bangkok, Thailand.

This partnership marks a significant milestone in making cutting-edge gene therapies accessible to patients under the Gene Therapy Early Access Program (EAP) — beginning with Spinal Muscular Atrophy (SMA).

The signing ceremony was attended by:
🧬 Professor Bruce Lahn, Founder of Lantu Biopharma
💼 Mr. Austin Gao, CEO of Lantu Biopharma
🌿 Mr. Ricky Koh, CEO of Icare Biotech
👨‍⚕ Dr. Lim Teck Onn and Dr. Lim Teck Chin, as witnesses

📸 Photo taken during the agreement signing in Bangkok. (In the photo above, from left to right: third person – Professor Bruce Lahn, fourth – Mr. Austin Gao, fifth – Mr. Ricky Koh, followed by Dr. Lim Teck Onn and Dr. Lim Teck Chin.)

The therapy is currently available only under the EAP framework and has not yet been commercially launched in other markets. All treatments are conducted under specialist supervision and in accordance with local medical guidelines.

hashtag#GeneTherapy hashtag#HealthcareInnovation hashtag#SMA hashtag#RareDisease hashtag#Biotech hashtag#IcareBiotech hashtag#LantuBiopharma hashtag#EarlyAccessProgram hashtag#Partnership